Molecular Basis of Loss Aversion

Sir Run Run Shaw Hospital1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2023年9月18日最近更新: 2023年9月26日

适应症

干预措施

试验速览

阶段: 不适用
状态: 招募中
发起方: Sir Run Run Shaw Hospital
入组人数: 60
试验地点: 1
主要终点: Choices to invest or not in the investment task

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Basic Science
盲法: Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围: 25 Years 至 40 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Age 25-40 years old (including boundary value).
•Elementary school education or above, able to understand the research content.
•Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.

排除标准

•Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
•Family history of genetic diseases.
•Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
•History of alcohol/drug dependence.
•Lactating women.
•The cardiopulmonary function test results are poor.
•Have ever taken madopar or propranolol for medical use.

研究组 & 干预措施

madopar-propranolol-placebo

Other

In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions.

干预措施: single-dose madopar, single-dose propranolol, and single-dose placebo by order (Drug)

madopar-placebo-propranolol

Other

In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions.

干预措施: single-dose madopar, single-dose placebo, and single-dose propranolol by order (Drug)

propranolol-madopar-placebo

Other

In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions.

干预措施: single-dose propranolol, single-dose madopar, and single-dose placebo by order (Drug)

propranolol-placebo-madopar

Other

In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions.

干预措施: single-dose propranolol, single-dose placebo, and single-dose madopar by order (Drug)

placebo-propranolol-madopar

Other

In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions.

干预措施: single-dose placebo, single-dose propranolol, and single-dose madopar by order (Drug)

placebo-madopar-propranolol

Other

In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.

干预措施: single-dose placebo, single-dose madopar, and single-dose propranolol by order (Drug)